RT Journal Article
SR Electronic
T1 Safety and Immunogenicity of Nanocovax, a SARS-CoV-2 Recombinant Spike Protein Vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.22.21260942
DO 10.1101/2021.07.22.21260942
A1 Nguyen, Thuy P.
A1 Do, Quyet
A1 Phan, Lan T.
A1 Dinh, Duc V.
A1 Khong, Hiep
A1 Hoang, Luong V.
A1 Nguyen, Thuong V.
A1 Pham, Hung N.
A1 Chu, Men V.
A1 Nguyen, Toan T.
A1 Le, Tri M.
A1 Tuyen, N.T.
A1 Dinh, Thanh T.
A1 Vo, Thuong V.
A1 Vu, Thao T.
A1 Nguyen, Quynh B.P.
A1 Phan, Vuong T.
A1 Nguyen, Luong V.
A1 Nguyen, Giang T.
A1 Tran, Phong M.
A1 Nghiem, Thuan D.
A1 Tran, Tien V.
A1 Nguyen, Tien G.
A1 Tran, Tuynh Q.
A1 Nguyen, Linh T.
A1 Do, Anh T.
A1 Nguyen, Dung D.
A1 Ho, Son A.
A1 Nguyen, Viet T.
A1 Pham, Dung T.
A1 Tran, Hieu B.
A1 Vu, Son T.
A1 Tran, Su X.
A1 Do, Trung M.
A1 Tran, Ton
A1 Cao, Thang M.
A1 Dao, Huy M.
A1 Nguyen, Thao T.T.
A1 Doan, Uyen Y
A1 Le, Vy T.T.
A1 Tran, Linh P.
A1 Nguyen, Ngoc M.
A1 Nguyen, Ngoc T.
A1 Pham, Hang T.T.
A1 Nguyen, Quan H.
A1 Nguyen, Hieu T.
A1 Trinh, Hung T.
A1 Nguyen, Hang L.K.
A1 Tran, Vinh T.
A1 Tran, Mai T.N.
A1 Nguyen, Truc T.T.
A1 Ha, Phat T.
A1 Huynh, Hieu T.
A1 Nguyen, Khanh D.
A1 Doan, Chung C.
A1 Do, Si M.
YR 2021
UL http://medrxiv.org/content/early/2021/07/25/2021.07.22.21260942.abstract
AB Background Nanocovax is a recombinant severe acute respiratory syndrome coronavirus 2 subunit vaccine composed of full-length prefusion stabilized recombinant SARS-CoV-2 spike glycoproteins (S-2P) and aluminum hydroxide adjuvant.Methods We conducted a dose-escalation, open label trial (phase 1) and a randomized, double-blind, placebo-controlled trial (phase 2) to evaluate the safety and immunogenicity of the Nanocovax vaccine (in 25 microgram (mcg), 50 mcg, and 75 mcg doses, aluminum hydroxide adjuvanted). In phase 1, 60 participants received two intramuscular injection of the vaccine following dose-escalation procedure. The primary outcomes were reactogenicity and laboratory tests to evaluate the vaccine safety. In phase 2 which involved in 560 healthy adults, the primary outcomes are vaccine safety; and anti-S IgG antibody response. Secondary outcomes were surrogate virus neutralization, wild-type SARS-CoV-2 neutralization, and T-cell responses by intracellular staining (ICS) for interferon gamma (IFNg). We performed primary analyses at day 35 and day 42.Results For phase 1 study, no serious adverse events (SAE) were observed for all 60 participants. Most adverse events (AE) were grade 1 and disappeared shortly after injection. For phase 2 study, after randomization, 480 participants were assigned to receive the vaccine with adjuvant, and 80 participants were assigned to receive placebo. Reactogenicity was absent or mild in the majority of participants and of short duration (mean, ≤3 days). Unsolicited adverse events were mild in most participants. There were no serious adverse events related to Nanocovax. Regarding the immunogenicity, Nanocovax induced robust anti-S antibody responses. There was no statistical difference in antibody responses among dose strengths on Day 42, in terms of anti S-IgG level and neutralizing antibody titer.Conclusions Up to 42 days, Nanocovax vaccine was safe, well tolerated and induced robust immune responses. We propose using Nanocovax 25 mcg for Phase 3 to evaluate the vaccine efficacy. (Research funded by Nanogen Pharmaceutical Biotechnology JSC., and the Ministry of Science and Technology of Vietnam; ClinicalTrials.gov number, NCT04683484.)Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04683484Funding StatementResearch funded by Nanogen Pharmaceutical Biotechnology JSC., and the Ministry of Science and Technology of VietnamAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The trial protocol was approved by the Ethics Committee/Protocol Review Board of the Ministry of Health (Vietnam) and was performed in accordance with the ICH-GCP good clinical practice guidelines, with an ethical policy consistent with the Declaration of Helsinki and applicable Vietnamese laws and regulations.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData will be provided upon request.